Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
07 janv. 2024 11h00 HE
|
Caribou Biosciences, Inc.
-- Tim Kelly to lead Caribou’s technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate...
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
12 déc. 2023 16h02 HE
|
Caribou Biosciences, Inc.
-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial...
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
07 nov. 2023 16h00 HE
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial continues enrolling second-line r/r LBCL patients in dose expansion; plan to share FDA feedback by year-end 2023 and report initial dose expansion data in H1 2024 -- ...
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
06 nov. 2023 08h00 HE
|
Caribou Biosciences, Inc.
-- Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma -- BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading...
Caribou Biosciences to Participate in Upcoming Investor Conferences
01 nov. 2023 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
18 oct. 2023 08h00 HE
|
Caribou Biosciences, Inc.
-- AMpLify Phase 1 clinical trial to initiate patient enrollment by mid-2024 -- -- CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption and immune cloaking to enter the...
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
27 sept. 2023 08h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...
Caribou Biosciences to Participate in Upcoming Investor Conferences
29 août 2023 16h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
08 août 2023 16h00 HE
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1...
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
13 juil. 2023 23h15 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of...